靶向糖基化修饰的抗肿瘤药物研发进展

Progress in the development of antitumor drugs targeting glycosylation modifications

糖基化作为一种普遍存在于细胞内外的生化过程,不仅对维持生物体的正常功能至关重要,其异常改变还与多种疾病的发生发展有着密切关联。在肿瘤疾病领域,糖基化不仅影响肿瘤细胞的增殖、迁移和侵袭能力,还与肿瘤的免疫逃逸密切相关。当前,针对糖基化相关过程的抗肿瘤靶向药物正成为新的研究热点。本文将从肿瘤相关糖类抗原、凝集素、糖基转移酶三个方面综述靶向糖基化相关过程的抗肿瘤药物研发进展。

Glycosylation,a ubiquitous biochemical process occurring both intracellularly and extracellularly,is crucial for the normal functioning of organisms,while its abnormal changes are often closely associated with the development of various diseases.In the field of oncology,glycosylation not only affects the proliferation,migration,and invasive capabilities of tumor cells,but is also significantly linked to immune evasion in cancer.Currently,targeted cancer therapies focusing on glycosylation-related processes are becoming a new research focus.This paper will review the development of targeted cancer drugs related to glycosylation processes from three aspects:tumorassociated carbohydrate antigens,lectins,and glycosyltransferases.